
    
      The study consisted of a 4-week Screening Period and a 26-week Randomized Treatment Period
      (Primary Evaluation Period). After completion of the Primary Evaluation Period, all
      participants had the opportunity to enter the Extension Period, wherein participants will
      receive ravulizumab for up to 3 years.

      This study is ongoing. The data presented is up to the Primary Completion date of the study
      and is for the Primary Evaluation Period. The results for the Extension Period will be
      reported after study completion.
    
  